These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9706064)

  • 1. Metrics comparing simulated early concentration profiles for the determination of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Chen ML
    Pharm Res; 1998 Aug; 15(8):1292-9. PubMed ID: 9706064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The duration of measuring partial AUCs for the assessment of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Balch AH; Chen ML
    Pharm Res; 1998 Mar; 15(3):399-404. PubMed ID: 9563068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.
    Ring A; Tothfalusi L; Endrenyi L; Weiss M
    Pharm Res; 2000 May; 17(5):583-8. PubMed ID: 10888310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence.
    Marston SA; Polli JE
    Pharm Res; 1997 Oct; 14(10):1363-9. PubMed ID: 9358548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.
    el-Tahtawy AA; Tozer TN; Harrison F; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):98-104. PubMed ID: 9487554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive and specific determination of the equivalence of absorption rates.
    Endrenyi L; Al-Shaikh P
    Pharm Res; 1995 Dec; 12(12):1856-64. PubMed ID: 8786956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
    Cho HY; Yoon H; Park GK; Lee YB
    Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion.
    Midha KK; Rawson MJ; McKay G; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 May; 43(5):244-54. PubMed ID: 15906590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel direct curve comparison metrics for bioequivalence.
    Polli JE; McLean AM
    Pharm Res; 2001 Jun; 18(6):734-41. PubMed ID: 11474775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method.
    Zintzaras E; Bouka P; Kowald A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):11-6. PubMed ID: 11996322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
    Hammami MM; De Padua SJS; Hussein R; Al Gaai E; Khodr NA; Al-Swayeh R; Alvi SN; Binhashim N
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):78. PubMed ID: 29216899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
    Rostami-Hodjegan A; Jackson PR; Tucker GT
    J Pharm Sci; 1994 Nov; 83(11):1554-7. PubMed ID: 7891273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical aspects of bioequivalence testing between two medicinal products.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin.
    Hsu LF
    Pharm Res; 2018 Mar; 35(5):106. PubMed ID: 29564719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.